Literature DB >> 6516458

The global distribution of Lyme disease.

G P Schmid.   

Abstract

Following the original description of erythema chronicum migrans (ECM) in Sweden in 1909, ECM became widely recognized in Europe. The first reported case of ECM acquired in the United States occurred in 1969, and in 1975 the full symptom complex now known as Lyme disease was recognized. In 1981, cases of Lyme disease were recognized in yet a third continent, Australia and, to date, cases acquired in at least 19 countries have been reported. Beginning with the original case reported in Sweden, clinical observations suggested that Ixodes ricinus ticks were a vector for ECM in Europe and the distribution of cases in Europe corresponds to the distribution of this tick, although one case outside this range has been reported following mosquito bites. Through similar observations, I. dammini and I. pacificus ticks have been established as vectors in the United States. In Australia, a vector has not been established, and none of the recognized vectors of Lyme disease occur there. The reporting of cases of Lyme disease from widely separated parts of the world involving multiple vectors suggests the disease may, in the future, be recognized in additional areas.

Entities:  

Mesh:

Year:  1984        PMID: 6516458      PMCID: PMC2590002     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  9 in total

1.  Erythema chronicum migrans (Afzelii) associated with mosquito bite.

Authors:  S Hård
Journal:  Acta Derm Venereol       Date:  1966       Impact factor: 4.437

2.  Erythema chronicum migrans.

Authors:  R J Scrimenti
Journal:  Arch Dermatol       Date:  1970-07

3.  Lyme disease in North Carolina.

Authors:  P S Pegram; C N Sessler; W L London
Journal:  South Med J       Date:  1983-06       Impact factor: 0.954

4.  Lyme disease-a tick-borne spirochetosis?

Authors:  W Burgdorfer; A G Barbour; S F Hayes; J L Benach; E Grunwaldt; J P Davis
Journal:  Science       Date:  1982-06-18       Impact factor: 47.728

5.  Lyme arthritis--report of a case in Arkansas.

Authors:  W R Thurlby
Journal:  J Ark Med Soc       Date:  1981-09

6.  Lyme arthritis in the Hunter Valley.

Authors:  A Stewart; J Glass; A Patel; G Watt; A Cripps; R Clancy
Journal:  Med J Aust       Date:  1982-02-06       Impact factor: 7.738

7.  Cases of Lyme disease in the United States: locations correlated with distribution of Ixodes dammini.

Authors:  A C Steere; S E Malawista
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities.

Authors:  A C Steere; S E Malawista; D R Snydman; R E Shope; W A Andiman; M R Ross; F M Steele
Journal:  Arthritis Rheum       Date:  1977 Jan-Feb

9.  Lyme disease challenges Australian clinicians: the implications of Australia's first reported case of Lyme arthritis.

Authors:  J R Fraser
Journal:  Med J Aust       Date:  1982-02-06       Impact factor: 7.738

  9 in total
  4 in total

1.  Immunogenic integral membrane proteins of Borrelia burgdorferi are lipoproteins.

Authors:  M E Brandt; B S Riley; J D Radolf; M V Norgard
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

2.  Host associations and seasonal abundance of immature Ixodes persulcatus (Acari: Ixodidae) in a Lyme-disease-endemic area in China.

Authors:  C X Ai; G C Qiu; Z X Shi; X M Wu; X D Liu; J H Zhao
Journal:  Exp Appl Acarol       Date:  1991-10       Impact factor: 2.132

3.  Immunochemical analysis of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug

4.  Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980-2015.

Authors:  Poojan Shrestha; Prabin Dahal; Chinwe Ogbonnaa-Njoku; Debashish Das; Kasia Stepniewska; Nigel V Thomas; Heidi Hopkins; John A Crump; David Bell; Paul N Newton; Elizabeth A Ashley; Philippe J Guérin
Journal:  BMC Med       Date:  2020-09-21       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.